Evidence map›Paper›PMID 41347838›Full record

ArticleInternational journal of molecular medicine2026

[Retracted] miR‑381 functions as a tumor suppressor by targeting ETS1 in pancreatic cancer.

Guanen Qiao, Jing Li, Jun Wang, Zhaoyang Wang, Wei Bian

Abstract readRetraction Notice
In one paragraph

Article in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Guanen QiaoDepartment of Digestion, The First Hospital of Handan City, Handan, Hebei 056002, P.R. China.
Jing LiDepartment of Digestion, The First Hospital of Handan City, Handan, Hebei 056002, P.R. China.
Jun WangDepartment of Digestion, The First Hospital of Handan City, Handan, Hebei 056002, P.R. China.
Zhaoyang WangDepartment of Infectious Diseases, The First Hospital of Handan City, Handan, Hebei 056002, P.R. China.
Wei BianDepartment of Hepatobiliary Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Following the publication of the above article, a concerned reader drew to the Editor's attention that, in Fig. 1D, the 'SW1990' and 'Bxpc‑3' data panels were overlapping, suggesting that these data were derived from the same original source where experiments showing different experimental conditions were intended to have been portrayed. In addition, further pairings of overlapping data panels were identified with the Ki67 assay data shown in Figs. 7E and the immunohistochemical data shown in Fig. 10C, suggesting that these figures had similarly been assembled incorrectly. Furthermore, four of the centrally placed flow cytometric plots featured in Fig. 5A appeared to be too similar in terms of the distribution of the data to be confident that these were all derived from independently performed experiments, and finally, some of the western blot data shown in Fig. 4B were strikingly similar to data which had already appeared in another paper, also published in

Indexed as

ETS1microRNA‑381pancreatic cancerphosphoinositide 3‑kinase/ AKT/mammalian target of rapamycin pathway

Identifiers

PMID41347838
PMCPMC12695153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.